CRON News and Press, Cronos Group Inc. From 11/12/23

2023-11-12 22:24:38 ET Summary Tilray stock has fallen 37.9% in 2023, despite being up 8.9% in 2023 in early September. The company's Q1 results were reported in October, along with the filing of the 10-Q. Tilray is still overvalued compared to its peers, despite the significa...

2023-11-11 06:58:12 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips I recently included Tilray (NASDAQ: TLRY ) stock in a list of three cannabis stocks to buy now. My rationale for recommending investors buy was I thought it could be success...

A recent study investigating the impact of CBD availability on opioid prescriptions has revealed that although legalizing CBD alone does not automatically reduce the rate of opioid prescriptions, making legal CBD products readily available and affordable has significantly reduced the number of o...

2023-11-10 07:33:34 ET More on Aurora, Canopy, etc. Aurora Cannabis Inc. 2024 Q2 - Results - Earnings Call Presentation Aurora Cannabis Inc. (ACB) Q2 2024 Earnings Call Transcript Canopy Growth Corporation (CGC) Q2 2024 Earnings Call Transcript Aurora Cannabi...

2023-11-08 12:15:16 ET Image source: The Motley Fool. Cronos Group (NASDAQ: CRON) Q3 2023 Earnings Call Nov 08, 2023 , 8:30 a.m. ET Operator Continue reading For further details see: Cronos Group (CRON) Q3 2023 Earnings Call Transcript

2023-11-08 11:29:05 ET Cronos Group Inc. (CRON) Q3 2023 Earnings Call Transcript November 08, 2023, 08:30 AM ET Company Participants Shayne Laidlaw - IR Mike Gorenstein - Chairman, President & CEO James Holm - CFO Conference Call Participants John...

2023-11-08 11:09:51 ET More on Cronos Group Cronos Group Q3 Preview: Don't Expect To Get High Cronos Group Q3 2023 Earnings Preview Canadian cannabis sector dips five years since legalization Seeking Alpha’s Quant Rating on Cronos Group Histori...

2023-11-08 07:36:24 ET More on Cronos Group Cronos Group Q3 Preview: Don't Expect To Get High Cronos Group Q3 2023 Earnings Preview Canadian cannabis sector dips five years since legalization Seeking Alpha’s Quant Rating on Cronos Group Histori...

Industry-leading balance sheet with $840 million in cash and short-term investments Net revenue in Q3 2023 increased by 22% year-over-year to $24.8 million ; on a constant currency basis, net revenue in Q3 2023 increased by 27% year-over-year to $26.0...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...